Redcare Pharmacy’s Prescription Boom Faces a Political Tailwind and a Profitability Squeeze

Redcare Pharmacy sees revenue surge 18% as German co-payment hikes drive demand, but heavy investments slash margins and send shares to €48, far below the €136 high.

The stars are aligning for Redcare Pharmacy’s core business, but the share price tells a different story. As the German government moves to increase patient co-payments for prescription drugs, the online pharmacy is poised to capture even more market share. Yet, the stock has cratered nearly 29% since the start of the year, trading at around €48—a far cry from its 52-week high of roughly €136.

Political Catalyst Meets Market Momentum

Berlin is turning up the heat on healthcare costs. A draft law passed by the cabinet this week proposes raising the co-payment range per prescription to between €7.50 and €15, up from the current maximum of €10. While the Bundestag still needs to debate the plan, the direction is clear: patients will face higher out-of-pocket expenses.

That dynamic plays directly into Redcare’s hands. Felix Dennl of Bankhaus Metzler argues the financial burden will push price-sensitive customers toward cheaper alternatives. With roughly two-thirds of Germany’s online prescription market already under its control, Redcare is well-positioned to benefit. A potential entry by rival Rossmann into this segment has been shelved, removing a competitive threat.

Revenue Surge, Margin Strain

The numbers for the first quarter already reflect the momentum. Group revenue jumped more than 18% to €848 million, beating the company’s own annual forecast. The prescription business in Germany was the standout, with sales soaring 55%.

But growth comes at a cost. Redcare is in the midst of a heavy investment cycle, pouring capital into a new logistics hub in Pilsen, Czech Republic, designed to expand capacity by millions of parcels. The spending spree has forced management to slash its medium-term margin target from over 8% to more than 5%. For the current year, the board expects an operating margin of at least 2.5%.

Digital Infrastructure as a Long-Term Bet

Behind the scenes, Redcare is building for efficiency. It became the first pharmacy to integrate a new access solution for Germany’s telematics infrastructure, replacing physical institutional cards with a purely digital identity. The system accelerates e-prescription processing and, over time, should streamline the cost base.

Analyst Divergence and the May 6 Reckoning

The market remains deeply divided on valuation. Barclays recently slashed its price target to €70, with analyst Guillaume Galland cutting revenue forecasts for the coming years. Jefferies, by contrast, still sees the stock at €150. The average analyst target sits at roughly €95, highlighting the uncertainty.

Technically, the stock is deeply oversold, with the relative strength index at an extreme 15.9 points. That suggests a potential rebound, but fundamentals will drive the next move.

All eyes are on May 6, when Redcare releases its full quarterly report. The event will be the first major test for new CFO Hendrik Krampe, a former Amazon executive. Investors want hard data on margins and cash flow, and CEO Olaf Heinrich—who is temporarily also running the commercial division—must convince the market that the heavy spending will soon yield measurable returns.